Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

Organogenesis Holdings Inc.

2025-Q1 EPS reported -$0.17 revenue$86,693,000

Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.
Net loss $18.8M ($0.17 loss per share) vs $2.1M loss in Q1 2024; adjusted EBITDA loss $12.5M vs income $2.6M.
Cash $110.5M, no debt; cash used in operations $19.9M vs $10.2M in prior year.
FY2025 revenue guidance reaffirmed at $480M-$535M; updated net income guidance $4.7M-$34.0M (from prior range).
ReNu BLA submission on track for end of 2025; second phase 3 study patient enrollment expected by end of Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.